Trial Information
Regulatory Post Marketing Surveillance Study on Nexavar®
Inclusion Criteria:
- Patients with diagnosis of advanced Renal Cell Carcinoma and Hepatocellular carcinoma
and decision taken by the physician to prescribe Nexavar
Exclusion Criteria:
- Hypersensitivity to the active substances or any of gradient of the study drug
ingredients (according to the local product information)
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Adverse events collection
Outcome Time Frame:
From start of treatment to 4 weeks after discontinuation of treatment
Safety Issue:
Yes
Principal Investigator
Bayer Study Director
Investigator Role:
Study Director
Investigator Affiliation:
Bayer
Authority:
South Korea: Korea Food and Drug Administration (KFDA)
Study ID:
14792
NCT ID:
NCT01012011
Start Date:
October 2009
Completion Date:
December 2014
Related Keywords:
- Carcinoma, Hepatocellular
- Carcinoma, Renal Cell
- Carcinoma, Hepatocellular
- Carcinoma, Renal Cell
- Carcinoma
- Carcinoma, Renal Cell
- Carcinoma, Hepatocellular